These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 6165491)

  • 1. In vitro sensitization of human lymphocytes to a myeloma cell-related antigen.
    Whitson ME; Griffin GD; Novelli GD; Solomon A
    Cell Immunol; 1981 May; 60(2):489-97. PubMed ID: 6165491
    [No Abstract]   [Full Text] [Related]  

  • 2. Human myeloma cells and their strong stimulating capacity in 'one-way' mixed lymphocyte reaction: a comparative study with leukaemic B lymphoid cells.
    Han T; Dadey B; Minowada J; Golde DW
    Immunology; 1979 Sep; 38(1):63-8. PubMed ID: 159862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Plasma cell antigens in human multiple myeloma.
    Mackenzie MR; Paglieroni TG
    J Lab Clin Med; 1977 May; 89(5):1009-17. PubMed ID: 67161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Spontaneous cell-mediated cytotoxicity and generation of HLA-unrelated cytotoxic effector cells during MLC in vitro.
    Leibold W; Gatti RA; Just S; Peter HH
    Transplant Proc; 1979 Jun; 11(2):1393-9. PubMed ID: 157578
    [No Abstract]   [Full Text] [Related]  

  • 5. In vitro-demonstration of cellular hypersensitivity to tumour antigens in man.
    Andersen V; Kjaer M; Bendixen G
    Ser Haematol; 1972; 5(5):3-21. PubMed ID: 4598039
    [No Abstract]   [Full Text] [Related]  

  • 6. Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens.
    Kim SK; Nguyen Pham TN; Nguyen Hoang TM; Kang HK; Jin CJ; Nam JH; Chung SY; Choi SJ; Yang DH; Kim YK; Chung IJ; Kim HJ; Lee JJ
    Ann Hematol; 2009 Nov; 88(11):1113-23. PubMed ID: 19277657
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor immunity to murine plasma cell tumors. V. Demonstration of a unique tumor antigen that is not associated with the myeloma idiotype.
    MacKenzie MR; Burton RC; Warner NL
    Int J Cancer; 1978 Jun; 21(6):789-95. PubMed ID: 78916
    [No Abstract]   [Full Text] [Related]  

  • 8. Studies on the pathogenesis of an immune defect in multiple myeloma.
    Paglieroni T; MacKenzie MR
    J Clin Invest; 1977 Jun; 59(6):1120-33. PubMed ID: 16939
    [TBL] [Abstract][Full Text] [Related]  

  • 9. B-cell differentiation antigen expressed on a human myeloma cell line (KMM-1).
    Togawa A; Inoue N; Mannoji M; Namba M
    Jpn J Clin Oncol; 1983 Sep; 13(3):511-5. PubMed ID: 6417374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induced expression of B7-1 on myeloma cells following retroviral gene transfer results in tumor-specific recognition by cytotoxic T cells.
    Tarte K; Zhang XG; Legouffe E; Hertog C; Mehtali M; Rossi JF; Klein B
    J Immunol; 1999 Jul; 163(1):514-24. PubMed ID: 10384156
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antigenic properties of human IgG Kappa and IgG lambda myeloma plasma cells.
    Hagner G
    Exp Hematol; 1983 Mar; 11(3):219-25. PubMed ID: 6403367
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro studies of lymphocytes from patients with plasma cell myeloma. II. Characterization by cell surface markers.
    Mellstedt H; Jondal M; Holm G
    Clin Exp Immunol; 1973 Nov; 15(3):321-30. PubMed ID: 4543556
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cellular reactions against Burkitt lymphoma cells. II. Effector cells obtained by allogeneic stimulation in mixed leukocyte cultures.
    Golub SH; Hewetson JF; Svedmyr EA; Singh S
    Int J Cancer; 1972 Jul; 10(1):150-6. PubMed ID: 4122453
    [No Abstract]   [Full Text] [Related]  

  • 14. Cell-mediated immune reactions to human tumors.
    Perlmann P; Troye M; Pape GR
    Cancer; 1977 Jul; 40(1 Suppl):448-57. PubMed ID: 69485
    [No Abstract]   [Full Text] [Related]  

  • 15. Melan-A/MART1 analog peptide triggers anti-myeloma T-cells through crossreactivity with HM1.24.
    Christensen O; Lupu A; Schmidt S; Condomines M; Belle S; Maier A; Hose D; Neuber B; Moos M; Kleist C; Terness P; Ho AD; Goldschmidt H; Klein B; Hundemer M
    J Immunother; 2009; 32(6):613-21. PubMed ID: 19483648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of antiserum against myeloma cells.
    Cawley LP; Goodwin WL; Minard BJ
    Cancer Res; 1973 Jan; 33(1):17-22. PubMed ID: 4629871
    [No Abstract]   [Full Text] [Related]  

  • 17. Alteration of the antigenicity of human lymphocytes by plant lectins and short-term tissue culture.
    Miller J; Lifton J; Hattler BG
    Cell Immunol; 1975 Oct; 19(2):306-17. PubMed ID: 53104
    [No Abstract]   [Full Text] [Related]  

  • 18. Idiotype-bearing and antigen-binding receptors produced by blood T lymphocytes in a case of human myeloma.
    Preud'homme JL; Klein M; Labaume S; Seligmann M
    Eur J Immunol; 1977 Dec; 7(12):840-6. PubMed ID: 75800
    [No Abstract]   [Full Text] [Related]  

  • 19. A permanent human cytotoxic T-cell line with high killing capacity against a lymphoblastoid B-cell line shows preference for HLA A, B target antigens and lacks spontaneous cytotoxic activity.
    Spits H; de Vries JE; Terhorst C
    Cell Immunol; 1981 Apr; 59(2):435-47. PubMed ID: 6169447
    [No Abstract]   [Full Text] [Related]  

  • 20. Sensitization of lymphocytes against pooled allogeneic cells. I. Generation of cytotoxicity against autologous human lymphoblastoid cell lines.
    Zarling JM; Bach FH
    J Exp Med; 1978 May; 147(5):1334-40. PubMed ID: 206649
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.